BOSTON SCIENTIFIC CORPBSX
BOSTON SCIENTIFIC CORP Financial Overview 2021–2025
Boston Scientific Corporation punctuated a multi-year acceleration with a 56.4% surge in reported net income for FY2025, validating a strategic pivot from steady-state device maker to high-growth compounder. Management has successfully layered aggressive M&A—highlighted by the $14.5 billion agreement for Penumbra—on top of organic hits like the FARAPULSE Pulsed Field Ablation System to dominate the cardiology and thrombectomy markets. The financial arc confirms this trajectory, as annual revenue expanded dramatically from $11.888 billion in FY2021 to $20.074 billion by the close of FY2025.
Operational velocity hit a peak in the most recent period, with FY2025 net sales growing 19.9%, outpacing the already strong 17.6% gain recorded in FY2024. This top-line expansion flowed directly to the bottom line, generating $2.898 billion in profit compared to just $642 million during the supply chain struggles of FY2022. Despite significant capital deployment for acquisitions like Silk Road Medical and Axonics, the balance sheet remains liquid with $1.965 billion in unrestricted cash. The market has priced in this escalated earnings power, with shares trading at $95.35 at the end of FY2025, reflecting confidence in the company's ability to integrate complex technologies while maintaining double-digit growth.
Recent Developments (Q3 and Q4 2025)
Operating momentum accelerated significantly leading into year-end, highlighted by a 20.3% revenue jump to $5.065 billion in Q3 2025. This growth was spearheaded by a 24.0% surge in the Cardiovascular segment and sustained demand for the Watchman device, pushing adjusted quarterly net income to $1.124 billion. Following these results, the company cemented its inorganic growth strategy with the definitive January 2026 merger agreement for Penumbra, structured to pay approximately 73% of the consideration in cash and 27% in stock.
Leadership changes are reshaping governance, with Peripheral Interventions President Jeffrey Mirviss retiring and long-time directors John Sununu and Yoshiaki Fujimori departing. The bull case rests on scalable efficiency, evidenced by $3.372 billion in adjusted net income through the first nine months of 2025. However, bears warn of valuation risk, as shares traded at a premium 61.0x earnings as of February 2026, leaving limited margin for error during complex integration efforts.
What to watch: Regulatory clearance milestones for the Penumbra transaction; board composition updates following director departures.
Rev
$16.75B
FY2024
NI
$1.85B
FY2024
EPS
$1.26
FY2024
OCF
$3.44B
FY2024
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
BOSTON SCIENTIFIC CORP 8-K Report, Executive Changes (Feb 5, 2026)
Boston Scientific Corporation (BSX) announced that Yoshiaki Fujimori, a long-serving member of its Board of Directors, will not seek re-election at the upcoming 2026 Annual Meeting of Stockholders. Mr. Fujimori, who has been on the Board since July 2016 and currently chairs the Risk, Science and Technology Committee, will continue in his roles until the annual meeting. His decision is reportedly not due to any disagreement with the company, which is a positive signal for stability. This departure represents a change in board composition, and the company's Board and Nominating and Governance Committee will assess the need for any adjustments to the Board's size and makeup following Mr. Fujimori's exit. Investors should monitor any future announcements regarding board appointments or restructuring to understand the company's strategic direction and governance evolution.
BOSTON SCIENTIFIC CORP 8-K Report, Financial Results (Feb 4, 2026)
Boston Scientific Corporation (BSX) has filed an 8-K report on February 4, 2026, to announce its financial results for the fourth quarter and full year ended December 31, 2025. The primary driver of this filing is the accompanying press release, furnished as Exhibit 99.1, which details the company's operational performance and financial condition for the periods mentioned. Investors should refer to this press release for specific figures and commentary regarding revenue, profitability, and any forward-looking statements. While the 8-K itself is procedural, the attached press release is critical for understanding BSX's recent performance. This filing serves as the official notification of the release of these important financial details. It's important to note that the information furnished under Item 2.02 is not considered "filed" for regulatory purposes, meaning it doesn't carry the same liability under Section 18 of the Exchange Act. However, it remains the primary source for investors to obtain the latest financial updates from the company.
BOSTON SCIENTIFIC CORP 8-K Report, Material Agreement (Jan 15, 2026)
Boston Scientific Corporation (BSX) announced a significant strategic move with the entry into a definitive Agreement and Plan of Merger to acquire Penumbra, Inc. This transaction, structured as a merger where Penumbra will become a wholly owned subsidiary of Boston Scientific, is expected to materially enhance Boston Scientific's product portfolio and market presence, particularly in high-growth areas of medical technology. The acquisition offers Penumbra shareholders a choice between cash and stock consideration, with a proration mechanism in place to balance the total cash and stock components. This structure provides flexibility to Penumbra's shareholders while aiming to optimize the financial and strategic integration for Boston Scientific. The deal is subject to customary closing conditions, including regulatory approvals and shareholder votes, and includes provisions for termination fees, outlining the commitment and potential implications for both parties.
BOSTON SCIENTIFIC CORP 8-K Report, Regulation FD Disclosure (Jan 15, 2026)
Boston Scientific Corporation (BSX) has announced a significant development in its growth strategy through the execution of a definitive agreement to acquire Penumbra, Inc. This "Transaction", as detailed in a joint press release and investor presentation, represents a major move by BSX to expand its market presence and product portfolio. The company has scheduled a conference call to discuss the implications and details of this acquisition. Investors should pay close attention to the upcoming filings, including the Form S-4 registration statement, which will contain more comprehensive information regarding the deal and its potential impact on Boston Scientific's future.
BOSTON SCIENTIFIC CORP 8-K Report, Executive Changes (Nov 19, 2025)
Boston Scientific Corporation (BSX) has filed an 8-K report detailing the approval of its 2026 Annual Bonus Plan and two new Performance Share Programs: the 2026 Relative Total Shareholder Return Performance Share Program (2026 rTSR PSP) and the 2026 Organic Net Sales Growth Performance Share Program (2026 Organic Net Sales PSP). These plans, effective for the 2026 performance year and subsequent periods, are designed to align executive compensation with company performance and shareholder interests. The annual bonus plan focuses on global sales, adjusted earnings per share, operating income, and sustainability goals, with potential payouts ranging from 0% to 225% of target bonuses based on company and individual performance. The performance share programs are designed as long-term incentives. The 2026 rTSR PSP will reward executives based on Boston Scientific's Total Shareholder Return relative to the S&P 500 Healthcare Index over a three-year period (2026-2028), with awards ranging from 0% to 200% of target. The 2026 Organic Net Sales PSP will incentivize executives based on the company's organic net sales growth over the same three-year period, also with award potential from 0% to 200% of target. Both performance share programs are subject to vesting criteria and clawback provisions, aligning with regulatory requirements.
View all 8-K filings →